摘要
目的:了解国内药物经济学评价研究现状,分析研究中存在的主要问题并提出建议。方法:检索2010年国内专业期刊上发表的药物经济学评价文献,根据制定的质量评价标准对纳入研究文献进行系统评估和质量评价。结果与结论:共纳入药物经济学评价文献117篇,主要研究机构为医疗机构,总体质量不高,大部分研究角度不明确、研究设计不合理、对照选择不恰当;成本计算差异大;健康产出指标、效果指标及评价方法都较单一;敏感性分析不合理;结果缺少对普适性、外推性和伦理性的讨论。
OBJECTIVE： To investigate the status quo of pharmacoeconomic evaluation studies in China and analyze existing problems to put forward suggestions. METHODS ： Pharmacoeconomic evaluation literatures published on domestic professional jour-nals in 2010 were searched. According to pharmacoeconomic quality evaluation criteria, the qualities of included literatures were evaluated systematically. RESULTS ＆ CONCLUSIONS： There are 117 literatures included, and the main research institutions are medical institutions; the overall quality of included studies is poor; perspective of most studies is not clear; design of study is not reasonable, and contrast is selected inappropriately; cost measurement varies in a wide range; health outcomes indicators, the effec-tiveness indicators and evaluation techniques are single; sensitivity analysis is not reasonable; discussion are absent about universali-ty, generalizability and ethics.
出处
《中国药房》
CAS
CSCD
2013年第26期2401-2404,共4页
China Pharmacy
关键词
药物经济学
评价研究
质量评价
Pharmacoeconomics
Evaluation studies
Quality evaluation
